Press releases

Chiesi Group delivers solid H1 2026 performance, combining growth, continued investment in innovation and positive economic impact across communities

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

Chiesi Group Announces New Chair and Vice Chair

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition

Chiesi Group Selects Salesforce Agentforce Life Sciences to Transform Customer Engagement

Chiesi and Bespak partner to advance Carbon Minimal Inhaler production with UK manufacturing site

Chiesi inaugurates the expansion of its industrial site in La Chaussée-Saint-Victor, a strategic investment towards sustainable respiratory options for patients

Chiesi Group accelerates sustainable growth in H1 2025, delivering strong financial results and reaffirming commitment to Shared Value

Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants

Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability

Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth

Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth

Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices